Cargando…

Risk of rash associated with vandetanib treatment in non-small-cell lung cancer patients: A meta-analysis of 9 randomized controlled trials

BACKGROUND: Vandetanib is a promising anticancer target agent for treating advanced carcinomas, such as non-small-cell lung cancer (NSCLC) and breast cancer. Rash is a frequently reported adverse event of vandetanib. We conducted this meta-analysis to determine the incidence rate and overall risks o...

Descripción completa

Detalles Bibliográficos
Autores principales:	Liu, Yuan, Qi, Manli, Hou, Shuping, Shao, Lili, Zhang, Junyan, Li, Yan, Liu, Quanzhong
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Wolters Kluwer Health 2017
Materias:	5700
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5671843/ https://www.ncbi.nlm.nih.gov/pubmed/29069010 http://dx.doi.org/10.1097/MD.0000000000008345

Ejemplares similares

Prognostic Value of Serum Tumor Markers in Medullary Thyroid Cancer Patients Undergoing Vandetanib Treatment
por: Werner, R.A., et al.
Publicado: (2015)

The Efficacy of Combining EGFR Monoclonal Antibody With Chemotherapy for Patients With Advanced Nonsmall Cell Lung Cancer: A Meta-Analysis From 9 Randomized Controlled Trials
por: Sheng, Jin, et al.
Publicado: (2015)

Glucagonoma syndrome with severe erythematous rash: A rare case report
por: Wang, Zhen-Xia, et al.
Publicado: (2019)

Angiogenesis inhibitors for the treatment of small cell lung cancer (SCLC): A meta-analysis of 7 randomized controlled trials
por: Li, Qing, et al.
Publicado: (2017)

Concurrent vs sequential chemoradiotherapy for patients with advanced non–small-cell lung cancer: A meta-analysis of randomized controlled trials
por: Xiao, Wei, et al.
Publicado: (2021)

The Risk of Neutropenia and Leukopenia in Advanced Non-Small Cell Lung Cancer Patients Treated With Erlotinib: A Prisma-Compliant Systematic Review and Meta-Analysis
por: Zhou, Jian-Guo, et al.
Publicado: (2015)

Chinese herbal medicine for small cell lung cancer patients: A protocol for a systematic review and meta-analysis
por: Mi, Xue, et al.
Publicado: (2020)

Efficacy and safety of Shenqi Fuzheng injection combined with platinum-based chemotherapy for stage III/IV non-small cell lung cancer: A protocol for systematic review and meta-analysis of randomized controlled trials
por: Chen, Hongwei, et al.
Publicado: (2019)

S-1-based concurrent chemoradiotherapy in the treatment of locally advanced non-small cell lung cancer: A systematic review and meta-analysis protocol
por: Liu, Feiyu, et al.
Publicado: (2018)

Efficacy of immune checkpoint inhibitors in the treatment of non-small cell lung cancer patients with different genes mutation: A meta-analysis
por: Zhang, Rui, et al.
Publicado: (2021)

The clinicopathological and prognostic significance of mTOR and p-mTOR expression in patients with non-small cell lung cancer: A meta-analysis
por: Qiu, Weiwei, et al.
Publicado: (2022)

Efficacy and safety of Kanglaite plus EGFR-TKI in the treatment of advanced non-small cell lung cancer: A meta-analysis of 13 RCTs
por: Li, Dailong, et al.
Publicado: (2022)

Poziotinib in non-small-cell lung cancer patients with HER2 exon 20 mutations: A pooled analysis of randomized clinical trials
por: Wang, Bi-Cheng, et al.
Publicado: (2022)

Vandetanib
por: Vozniak, J. Michael, et al.
Publicado: (2012)

Effects of 9 oral care solutions on the prevention of oral mucositis: a network meta-analysis of randomized controlled trials
por: Yu, Ya-Ying, et al.
Publicado: (2020)

Clinical efficacy and safety of Huachansu injection combination with platinum-based chemotherapy for advanced non-small cell lung cancer: A systematic review and meta-analysis of randomized controlled trials
por: Tan, Xinmei, et al.
Publicado: (2021)

Efficacy and safety of icotinib in the treatment of advanced EGFR mutation-positive nonsmall cell lung cancer: A meta-analysis of randomized controlled trials
por: Li, Dailong, et al.
Publicado: (2022)

Prognostic value of pretreatment modified Glasgow Prognostic Score in small cell lung cancer: A meta-analysis
por: Xie, Yulian, et al.
Publicado: (2023)

Pretreatment “prognostic nutritional index” as an indicator of outcome in lung cancer patients receiving ICI-based treatment: Systematic review and meta-analysis
por: Shao, Yifeng, et al.
Publicado: (2022)

Twice-daily vs higher-dose once-daily thoracic radiotherapy for limited-disease small-cell lung cancer: A PRISMA-compliant meta-analysis
por: Yang, Lin, et al.
Publicado: (2020)

Erlotinib plus tivantinib versus erlotinib alone in patients with previously treated stage IIIb/IV non–small-cell lung cancer: A meta-analysis based on randomized controlled trials
por: Deng, Huan, et al.
Publicado: (2020)

Clinicopathological and prognostic significance of SMAD4 in non-small cell lung cancer: A meta-analysis and database validation
por: Li, Zhiqiang, et al.
Publicado: (2023)

The role of amplified in breast cancer 1 in breast cancer: A meta-analysis
por: Hou, Jianjing, et al.
Publicado: (2020)

Lentinan combined with cisplatin for the treatment of non-small cell lung cancer
por: Zhao, Chenchen, et al.
Publicado: (2021)

Efficacy and safety of cinobufacini injection combined with vinorelbine and cisplatin regimen chemotherapy for stage III/IV non-small cell lung cancer: A protocol for systematic review and meta-analysis of randomized controlled trials
por: Li, Qian, et al.
Publicado: (2020)

Platinum versus immunotherapy for early resectable non-small cell lung cancer: A protocol for systematic review and meta analysis
por: Tong, Zhangwei, et al.
Publicado: (2020)

BIM Gene Polymorphism Lowers the Efficacy of EGFR-TKIs in Advanced Nonsmall Cell Lung Cancer With Sensitive EGFR Mutations: A Systematic Review and Meta-Analysis
por: Huang, Wu Feng, et al.
Publicado: (2015)

A meta-analysis on the relationship of exosomes and the prognosis of lung cancer
por: Xiang, Hui, et al.
Publicado: (2021)

LKB1 expression and the prognosis of lung cancer: A meta-analysis
por: Lin, Chunxuan, et al.
Publicado: (2021)

Efficacy of Addition of Antiangiogenic Agents to Taxanes-Containing Chemotherapy in Advanced Nonsmall-Cell Lung Cancer: A Meta-Analysis and Systemic Review
por: Sheng, Jin, et al.
Publicado: (2015)

High Incidence of EGFR Mutations in Pneumonic-Type Non-Small Cell Lung Cancer
por: Liu, Jun, et al.
Publicado: (2015)

Gefitinib provides similar effectiveness and improved safety than erlotinib for advanced non-small cell lung cancer: A meta-analysis
por: Zhang, Wenxiong, et al.
Publicado: (2018)

The relationship between hepatoma-derived growth factor and prognosis in non-small cell lung cancer: A systematic review and meta-analysis
por: Koh, Hyun Min, et al.
Publicado: (2020)

Prognostic impact of the pre-treatment controlling nutritional status score in patients with non-small cell lung cancer: A meta-analysis
por: Peng, Jing, et al.
Publicado: (2021)

Efficacy and safety of endostar combined with cisplatin in treatment of non-small cell lung cancer with malignant pleural effusion: A meta-analysis
por: Hu, Yongqi, et al.
Publicado: (2022)

Clinical significance of high expression of proliferating cell nuclear antigen in non-small cell lung cancer
por: Ye, Xiaolan, et al.
Publicado: (2020)

Mining prognostic factors of extensive-stage small-cell lung cancer patients using nomogram model
por: Gao, Hongxiang, et al.
Publicado: (2020)

S-1 monotherapy versus S-1 combination therapy in gemcitabine-refractory advanced pancreatic cancer: A meta-analysis (PRISMA) of randomized control trials
por: Zhong, Sheng, et al.
Publicado: (2017)

Surgical Intervention Improves Survival for Metastatic Non-Small Cell Lung Cancer Patients
por: Shen, Hong, et al.
Publicado: (2016)

The Adverse Events of Oxycodone in Cancer-Related Pain: A Systematic Review and Meta-Analysis of Randomized Controlled Trials
por: Ma, Hu, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_uaa0d6an090d29hjf9m1qje7a8